The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Open accessAbstract
BACKGROUND: Levels of high-density lipoprotein (HDL) cholesterol are inversely related to cardiovascular risk. Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, increases HDL cholesterol levels, but the functional effects associated with this mechanism remain uncertain. METHODS: A total of 1188 patients with coronary disease underwent intravascular ultrasonography. After treatment with atorvastatin to reduce levels of low-density lipoprotein (LDL) cholesterol to less than 100 mg per deciliter (2.59 mmol per liter), patients were randomly assigned to receive either atorvastatin monotherapy or atorvastatin plus 60 mg of torcetrapib daily. After 24 months, disease progression was measured by repeated intravascular ultrasonography in 910 patients (77%). RESULTS: After 24 months, as compared with atorvastatin monotherapy, the effect of torcetrapib-atorvastatin therapy was an approximate 61% relative increase in HDL cholesterol and a 20% relative decrease in LDL cholesterol, reaching a ratio of LDL cholesterol to HDL cholesterol of less than 1.0. Torcetrapib was also associated with an increase in systolic blood pressure of 4.6 mm Hg. The percent atheroma volume (the primary efficacy measure) increased by 0.19% in the atorvastatin-only group and by 0.12% in the torcetrapib-atorvastatin group (P=0.72). A secondary measure, the change in normalized atheroma volume, showed a small favorable effect for torcetrapib (P=0.02), but there was no significant difference in the change in atheroma volume for the most diseased vessel segment. CONCLUSIONS: The CETP inhibitor torcetrapib was associated with a substantial increase in HDL cholesterol and decrease in LDL cholesterol. It was also associated with an increase in blood pressure, and there was no significant decrease in the progression of coronary atherosclerosis. The lack of efficacy may be related to the mechanism of action of this drug class or to molecule-specific adverse effects. (ClinicalTrials.gov number, NCT00134173 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Self-citationMintz, G. S., Nissen, S. E., Anderson, W. D., Bailey, S. R., Erbel, R., Fitzgerald, P. J., Pinto, F. J., Rosenfield, K., Siegel, R. J., Tuzcu, E. M., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01175-5 · Cited by 2,185
Self-citationNissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Self-citationBrown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationStatin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Self-citationNissen, S. E., Tuzcu, E. M., Libby, P., Thompson, P. D., Ghali, M., Garza, D., Berman, L., Shi, H., Buebendorf, E., Topol, E. J., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2217 · Cited by 1,154
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 861
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Zheng, L., Nukuna, B., Brennan, M.-L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421109 · Cited by 737
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tuzcu, E. M., Brewer, H. B., Sipahi, I., Nicholls, S. J., Ganz, P., Schoenhagen, P., Waters, D. D., Pepine, C. J., Crowe, T. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054699 · Cited by 398
Self-citationLibby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388
Shah, P. K., Kaul, S., Nilsson, J., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4501.098468 · Cited by 295
Matsuura, F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27602 · Cited by 293
Hirano, K.-I., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., & Matsuzawa, Y. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1053 · Cited by 275
Agerholm-Larsen, B., Nordestgaard, B. G., Steffensen, R., Jensen, G., & Tybjærg-Hansen, A. (2000) · Circulation · doi:10.1161/01.cir.101.16.1907 · Cited by 267
The Failure of Torcetrapib: Was it the Molecule or the Mechanism?
Tall, A. R., Yvan-Charvet, L., & Wang, N. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000256728.60226.77 · Cited by 267
Tardif, J.-C., Grégoire, J., L’Allier, P. L., Anderson, T. J., Bertrand, O., Reeves, F., Title, L. M., Alfonso, F., Schampaert, E., Hassan, A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147777.12010.ef · Cited by 252
Self-citationMechanisms of Disease: proatherogenic HDL—an evolving field
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., & Fogelman, A. M. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0245 · Cited by 249
Shah, P. K., Kaul, S., Nilsson, J., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4401.098467 · Cited by 222
Sipahi, I., Tuzcu, E. M., Schoenhagen, P., Wolski, K. E., Nicholls, S. J., Balog, C., Crowe, T. D., & Nissen, S. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.045 · Cited by 199
Self-citationMorehouse, L. A., Sugarman, E. D., Bourassa, P.-A., Sand, T. M., Zimetti, F., Gao, F., Rothblat, G. H., & Milici, A. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m600332-jlr200 · Cited by 171
Kuivenhoven, J. A., de Grooth, G. J., Kawamura, H., Klerkx, A. H., Wilhelm, F., Trip, M. D., & Kastelein, J. J. P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.12.064 · Cited by 170
Vascular Biomarkers and Surrogates in Cardiovascular Disease
Tardif, J.-C., Heinonen, T., Orloff, D., & Libby, P. (2006) · Circulation · doi:10.1161/circulationaha.105.598987 · Cited by 163
Self-citationMcKenney, J. M., Davidson, M. H., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.066 · Cited by 144
Self-citationPros and cons of inhibiting cholesteryl ester transfer protein
Hirano, K., Yamashita, S., & Matsuzawa, Y. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200012000-00004 · Cited by 85
Klerkx, A. H. E. M., Harchaoui, K. E., van der Steeg, W. A., Boekholdt, S. M., Stroes, E. S. G., Kastelein, J. J. P., & Kuivenhoven, J. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000205595.19612.c9 · Cited by 81
Schoenhagen, P., Sapp, S. K., Tuzcu, E. M., Magyar, W. A., Popovich, J., Boumitri, M., Vince, D. G., Crowe, T., & Nissen, S. E. (2003) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2003.45 · Cited by 53
Self-citationPartial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma
Morton, R. E., & Greene, D. J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.06.030 · Cited by 15
Cited by
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationAuthors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
Self-citationEffect of Two Intensive Statin Regimens on Progression of Coronary Disease
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., Borgman, M., Wolski, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110874 · Cited by 890
Self-citationNissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Self-citation
Metadata
- Authors
- Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-29
- Volume
- 356
- Issue
- 13
- Pages
- 1304-1316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973355122
- Cited by
- 966
- References
- 32
- FWCI
- 137.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.